LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
LIGAND PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$297.28+1.74 (+0.59%)
Close on Oct 19, 2026
- Market cap
- $6.49B
- P/E (TTM)
- 31.6
- Dividend yield
- –
LIGAND PHARMACEUTICALS INC revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalties | $48.03M | $42.96M | $50.53M | $46.59M | $36.40M | $27.49M | $34.81M | $31.71M | $23.16M | $19.10M | $22.49M | $23.89M | 75.4% | +32.0% |
| Revenue from intangible royalty assets | $37.36M | $32.93M | $40.70M | $40.16M | $30.08M | $21.59M | $27.82M | $26.55M | $22.60M | $18.36M | $22.46M | $23.86M | 58.7% | +24.2% |
| Filspari | $13.57M | $11.32M | $11.01M | $9.08M | $6.58M | $5.30M | $4.78M | $3.21M | $2.42M | $1.77M | $948.00K | $1.12M | 21.3% | +106.2% |
| Income from financial royalty assets | $10.67M | $10.03M | $9.83M | $6.43M | $6.31M | $5.90M | $6.99M | $5.16M | $559.00K | $738.00K | $23.00K | $25.00K | 16.8% | +69.0% |
| Captisol | $7.98M | $8.65M | $7.79M | $10.67M | $8.29M | $13.46M | $7.92M | $6.26M | $7.50M | $9.21M | $3.92M | $8.61M | 12.5% | -3.7% |
| Contract revenue and income | $7.68M | $110.00K | – | $58.20M | $2.94M | $4.38M | $89.00K | $13.85M | $10.87M | $2.67M | $1.69M | $372.00K | 12.1% | +161.1% |
| Contract revenue and income | $7.68M | $110.00K | – | – | $2.94M | $4.38M | – | – | – | – | – | – | 12.1% | +161.1% |
| Kyprolis | $7.04M | $6.74M | – | $11.62M | $8.80M | $4.72M | – | $11.60M | $9.00M | $6.63M | – | $10.54M | 11.1% | -20.0% |
| Qarziba | $6.15M | $6.30M | $6.44M | $5.98M | $5.89M | $5.44M | $6.49M | $4.63M | $0 | $0 | – | – | 9.7% | +4.5% |
| Income | $5.00M | – | – | $5.00M | $1.02M | $0 | – | $0 | $0 | $1.94M | – | $0 | 7.9% | +391.6% |
| Other | $4.27M | $3.76M | – | $3.42M | $2.56M | $3.67M | – | $1.73M | $2.00M | $2.18M | – | – | 6.7% | +66.5% |
| Ohtuvayre | $4.14M | $2.99M | – | – | $2.08M | $1.41M | – | – | – | – | – | – | 6.5% | +98.8% |
| Ohtuvayre inventors | $3.29M | $3.05M | – | – | $0 | $0 | – | – | – | – | – | – | 5.2% | – |
| Rylaze | $3.20M | $3.22M | – | $3.56M | $2.86M | $3.12M | – | $3.89M | $3.23M | $2.95M | – | $3.68M | 5.0% | +11.8% |
| Contract revenue | $2.68M | $110.00K | $60.43M | $131.00K | $1.93M | $4.38M | $2.03M | $13.85M | – | – | $667.00K | $397.00K | 4.2% | +39.3% |
| Capvaxive | $2.32M | $1.97M | $3.72M | $3.21M | $2.25M | $885.00K | $191.00K | $435.00K | – | – | – | – | 3.6% | +2.9% |
| Teriparatide injection | $1.47M | $1.32M | – | $2.63M | $2.30M | $1.19M | – | $2.38M | $2.10M | $2.04M | – | $2.80M | 2.3% | -36.0% |
| Vaxneuvance | $1.35M | $1.61M | $1.44M | $2.04M | $2.64M | $1.29M | $1.22M | $1.47M | $1.11M | $1.39M | $1.07M | $1.31M | 2.1% | -48.9% |
| Other | $1.23M | $681.00K | $3.39M | $449.00K | $428.00K | $460.00K | $498.00K | $529.00K | $559.00K | $738.00K | – | – | 1.9% | +186.4% |
| Milestone | – | – | – | – | – | – | – | – | – | – | $1.50M | $0 | – | – |
| Evomela | – | – | – | $1.89M | $1.47M | $1.98M | – | $1.75M | $2.73M | $1.40M | – | $2.50M | – | – |
| Contract revenue | – | – | – | – | – | – | – | – | – | – | $17.45M | $263.00K | – | – |
| Other | – | – | – | – | – | – | – | – | – | – | – | $134.00K | – | – |
| Captisol | – | – | – | – | – | – | – | – | – | – | $3.92M | $8.61M | – | – |
| Captisol - COVID | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
| Other | – | – | – | – | – | – | $1.03M | $2.27M | $2.00M | $2.18M | $1.50M | $1.92M | – | – |
| Milestone and other | – | – | – | – | $1.93M | $4.38M | – | $13.85M | $10.87M | $727.00K | – | $372.00K | – | – |
| Income from Pelthos Transaction | – | – | $0 | $53.07M | – | – | $0 | $0 | – | – | – | – | – | – |
| Ohtuvayre | – | – | $3.55M | $2.72M | – | – | $720.00K | $112.00K | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Ligand Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.